
    
      This is an open-label, non-randomised, single-sequence 2-part study. Enrolment into Part 2 of
      the study will begin after Part 1 is complete, and a review of safety and pharmacokinetic
      data has been completed.Part 1 will assess the safety, tolerability and pharmacokinetics of
      single doses of FDL176 with and without co-administration of FDL169. Part 2 will assess the
      safety, tolerability and pharmacokinetics of repeated doses of FDL176 once daily (QD) with
      and without co-administration of FDL169.
    
  